Amy L. Goodrich, RN BSN, MSN, CRNP-AC (Johns Hopkins)
Learning Objectives
At the conclusion of this activity, learners will be better able to:
- Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with hematologic malignancies
- Discuss prescribed bispecific antibody–based therapeutic strategies with patients with hematologic malignancies and their caregivers, taking into consideration current indications, safety profiles, and administration considerations
- Manage and mitigate adverse events associated with bispecific antibody treatment in patients with hematologic malignancies
- Identify patients with hematologic malignancies who may be eligible for ongoing clinical trials evaluating currently available and emerging bispecific
BETH FAIMAN PHD, RN, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO
Learning Objectives:
• Integrate the latest molecular and biomarker testing guidance for the identification of oncogenic drivers in patients with early-stage NSCLC
• Determine the most appropriate perioperative treatment strategy that incorporates patient-specific factors and the results obtained from biomarker testing
• Determine if individual patients with resectable early-stage NSCLC who are candidates for enrollment in an ongoing investigational clinical trial based on the presence of an ALK fusion, and counsel patients on the investigational therapies targeting ALK
PRESENTERS
Click on each link below for a printable file.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review evolving treatment options in relapsed/refractory multiple myeloma (RRMM) and clinical implications
- Examine how academic and tertiary care centers have integrated new treatments into practice in the setting of RRMM
- Identify the most common and the unique chronic toxicities associated with long-term treatment of multiple myeloma
- Describe the core principles surrounding mitigating and managing chronic toxicities in patients being treated in the RRMM setting
- Outline the expanding roles of nurses, advance practice providers and nurse navigators when patients are treated with newer options in the RRMM setting
Teresa Knoop, RN
Learning objectives:
- Differentiate the mechanisms of action (MOAs) of novel therapeutic strategies for advanced renal cell carcinoma (RCC)
- Appraise the efficacy and safety profiles of novel immunotherapies and targeted therapies for advanced RCC
- Assess strategies to optimize treatment safety and tolerability and ensure the provision of patient-centered RCC care
Nazy Zomorodian, RNC, MSN, CUNP, CCRC, is a nurse practitioner in the Department of Urology at the University of California Los Angeles (UCLA) Medical Center, where she is also the Director of Genitourinary (GU) Clinical Trials. In addition, she is an Assistant Professor of Urology at the David Geffen School of Medicine at UCLA and is certified by the Association of Clinical Research Professionals as a Clinical Research Coordinator. Ms. Zomorodian specializes in the treatment of patients with genitourinary malignancies, including kidney, prostate, and bladder cancer, and her research focuses on developing novel therapeutics and improving outcomes for patients with these diseases.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the efficacy and safety profiles and current clinical roles of TROP-targeting ADCs in TNBC and HR+, HER2- MBC
- Mitigate adverse events associated with different TROP2-targeting ADCs in TNBC and HR+, HER2- MBC
- Apply best practices for patient education and provision of team-based, patient-centric, equitable care to all patients with TNBC and HR+, HER2- MBC, including those in underserved communities
Patricia A. Mangan, MSN, CRNP
Nazy Zomorodian, MSN, CUNP
Jamie Carroll, APRN, CNP, MSN
Mayo Clinic
Rochester, Minnesota
Chuck Dukas
OCS 2024 Master of Ceremonies and Host
Nikka Berkowitz, AGACNP-BC
Copyright 2024 GLAONS All rights reserved.
Sanjay Juneja, MD